Bioventus Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
BVS$11.18+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(Amounts in thousands)
| 2024 | 2023 | 2022 | |
|---|---|---|---|
| Operating activities: | |||
| Net loss | $(43,833) | $(195,625) | $(213,391) |
| Less: Loss from discontinued operations, net of tax | — | (74,429) | (68,740) |
| Loss from continuing operations | (43,833) | (121,196) | (144,651) |
| Adjustments to reconcile net loss to net cash from operating activities: | |||
| Depreciation and amortization | 49,555 | 57,365 | 55,398 |
| (Benefit) provision for expected credit losses | (434) | (1,103) | 5,190 |
| Equity-based compensation from 2021 Stock Incentive Plan | 10,058 | 2,722 | 17,585 |
| Change in fair value of contingent consideration | 1,423 | 719 | 1,102 |
| Change in fair value of interest rate swap | — | — | (6,396) |
| Deferred income taxes | (5,394) | (2,377) | (46,658) |
| Impairments of assets | 36,357 | 78,615 | 134,982 |
| Loss on disposals | 292 | 3,577 | — |
| Unrealized (gain) loss on foreign currency fluctuations | (259) | 665 | 1,383 |
| Other, net | 2,810 | 1,707 | 388 |
| Changes in operating assets and liabilities: | |||
| Accounts receivable | (10,666) | 10,055 | (17,672) |
| Inventory | (16,435) | (5,991) | (18,618) |
| Accounts payable and accrued expenses | 17,846 | (5,275) | (3,099) |
| Other current and noncurrent assets and liabilities | (2,525) | (1,970) | 9,659 |
| Net cash from operating activities - continuing operations | 38,795 | 17,513 | (11,407) |
| Net cash from operating activities - discontinued operations | — | (2,169) | (2,130) |
| Net cash from operating activities | 38,795 | 15,344 | (13,537) |
| Investing activities: | |||
| Proceeds from sale of a business | 24,678 | 34,675 | — |
| Purchase of property and equipment | (1,006) | (7,362) | (1,478) |
| Investments and acquisition of distribution rights | (709) | — | (10,042) |
| Other | — | — | (75) |
| Net cash from investing activities - continuing operations | 22,963 | 27,313 | (11,595) |
| Net cash from investing activities - discontinued operations | — | (11,506) | (104,841) |
| Net cash from investing activities | 22,963 | 15,807 | (116,436) |
| Financing activities: | |||
| Proceeds from issuance of Class A and B common stock | 2,442 | 778 | 5,822 |
| Tax withholdings on equity-based compensation | — | — | (3,352) |
| Receipt of deferred consideration | 4,500 | — | — |
| Borrowing on revolver | — | 64,000 | 25,000 |
| Payment on revolver | (15,000) | (49,000) | (25,000) |
| Proceeds from the issuance of long-term debt, net of issuance costs | — | — | 79,659 |
| Debt financing costs | (1,180) | (3,661) | — |
| Payments on long-term debt | (44,584) | (38,264) | (20,038) |
| Other, net | (758) | (506) | (15) |
| Net cash from financing activities | (54,580) | (26,653) | 62,076 |
| Effect of exchange rate changes on cash | (2,560) | 629 | 521 |
| Net change in cash, cash equivalents and restricted cash | 4,618 | 5,127 | (67,376) |
| Cash, cash equivalents and restricted cash at the beginning of the period | 36,964 | 31,837 | 99,213 |
| Cash, cash equivalents and restricted cash at the end of the period | $41,582 | $36,964 | $31,837 |
| Supplemental disclosure of noncash investing and financing activities | |||
| Accrued liabilities for distribution rights and member distributions | $— | $709 | $— |
| Accounts payable for purchase of property, plant and equipment | $42 | $1,311 | $419 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.